Growth differentiation factor-15 as a clinical biomarker of frailty, sarcopenia and functional decline: A systematic literature review.

Ainsley Ryan Yan Bin Lee, S Nachammai Vidhya, Anjin Hong, Weiling Amanda Tan, Chun En Yau, Chen Ee Low, Reshma Aziz Merchant

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ministry of Health Holdings, Singapore.Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ministry of Health Holdings, Singapore. · pubmed

Paper

Abstract

With an aging population globally, prevention of frailty and sarcopenia will become a public health priority. Growth Differentiation Factor-15 (GDF-15), a stress-responsive cytokine of the TGF-β superfamily, has emerged as a promising biomarker linking mitochondrial dysfunction, cellular senescence, and systemic inflammation to biological and phenotypic aging.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Growth Differentiation Factor-15 (GDF-15) serves as a clinical biomarker for frailty, sarcopenia, and functional decline in aging populations. The paper is relevant as it addresses biological markers that may link to underlying mechanisms of aging and age-related decline, contributing to the understanding of frailty and sarcopenia as critical aspects of longevity research.

Author of this paper? Send a correction.